Published on October 29, 2009 at 7:52 AM
Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference. The 2009 Congress takes place November 1st - 5th at the Shanghai International Convention Center.
Dr. Peter Pommerville, M.D., Principal Investigator from the lead site at Can-Med Clinical Research Centre (Victoria, B.C.), will present the data. The moderated poster presentation, entitled "PRX302 is a transperineally administered, PSA-activated protoxin that produces symptomatic relief in men with moderate to severe BPH", will be presented on November 2nd at 3:15pm.
Based on the very promising results from this open label Phase 2 study, the Company initiated a double-blinded Phase 2 placebo controlled clinical trial called TRIUMPH in the first quarter of 2009. The Company recently announced that enrollment of this study is complete and anticipate top-line results in the fourth quarter of 2009.
Source: PROTOX THERAPEUTICS INC.
93d8fb42-05f8-43e0-85b4-baa69de12606|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Benign Prostatic Hyperplasia, Brain, Brain Cancer, Cancer, Cell, Hyperplasia, Incontinence, Placebo, Prostate Cancer, Prostate-Specific Antigen, Sexual Dysfunction